Integrating Therapies for Alcohol Use Disorder in Alcohol-Associated Hepatitis Clinical Trials: Advancing Composite Endpoints for Improved Outcomes
Posted inGastroenterology Internal Medicine news

Integrating Therapies for Alcohol Use Disorder in Alcohol-Associated Hepatitis Clinical Trials: Advancing Composite Endpoints for Improved Outcomes

Alcohol-associated hepatitis (AH) carries high morbidity and mortality, with no approved therapies addressing both liver injury and alcohol misuse. This article explores integrated trial designs using composite endpoints combining liver and alcohol-related outcomes, exemplified by the ITAALD trial.
Designing Rigorous Trials of Systemic Therapy with Surgery and Locoregional Treatment in Hepatocellular Carcinoma: Key Recommendations from an HCC-Live Expert Consensus
Posted inGastroenterology news Oncology

Designing Rigorous Trials of Systemic Therapy with Surgery and Locoregional Treatment in Hepatocellular Carcinoma: Key Recommendations from an HCC-Live Expert Consensus

A multidisciplinary consensus provides practical, trial-design focused recommendations for testing systemic therapies around surgery or combined with locoregional treatment in hepatocellular carcinoma, emphasizing patient selection, endpoints, safety, and statistical strategies.
Long-Term Durability and Clinical Stability of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A 54-Month Synthesis
Posted inCardiology Clinical Updates Diabetes & Endocrinology news

Long-Term Durability and Clinical Stability of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A 54-Month Synthesis

This review synthesizes the 54-month results of the ATTRibute-CM open-label extension, demonstrating that early and continuous acoramidis treatment provides sustained reductions in mortality and cardiovascular hospitalizations while maintaining functional capacity and biomarker stability in ATTR-CM patients.